- Home
- ANIX vs PRLD Comparison
ANIX vs PRLD Comparison
Compare ANIX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- PRLD
- Stock Information
- Founded
- ANIX 1982
- PRLD 2016
- Country
- ANIX United States
- PRLD United States
- Employees
- ANIX N/A
- PRLD N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- ANIX Health Care
- PRLD Health Care
- Exchange
- ANIX Nasdaq
- PRLD Nasdaq
- Market Cap
- ANIX 84.7M
- PRLD 73.7M
- IPO Year
- ANIX 1987
- PRLD 2020
- Fundamental
- Price
- ANIX $2.38
- PRLD $0.66
- Analyst Decision
- ANIX Strong Buy
- PRLD Strong Buy
- Analyst Count
- ANIX 3
- PRLD 2
- Target Price
- ANIX $9.00
- PRLD $4.50
- AVG Volume (30 Days)
- ANIX 69.9K
- PRLD 271.5K
- Earning Date
- ANIX 06-03-2025
- PRLD 05-06-2025
- Dividend Yield
- ANIX N/A
- PRLD N/A
- EPS Growth
- ANIX N/A
- PRLD N/A
- EPS
- ANIX N/A
- PRLD N/A
- Revenue
- ANIX N/A
- PRLD $7,000,000.00
- Revenue This Year
- ANIX N/A
- PRLD N/A
- Revenue Next Year
- ANIX N/A
- PRLD N/A
- P/E Ratio
- ANIX N/A
- PRLD N/A
- Revenue Growth
- ANIX N/A
- PRLD N/A
- 52 Week Low
- ANIX $2.07
- PRLD $0.61
- 52 Week High
- ANIX $4.20
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- ANIX 28.31
- PRLD 42.82
- Support Level
- ANIX $2.67
- PRLD $0.61
- Resistance Level
- ANIX $2.97
- PRLD $0.72
- Average True Range (ATR)
- ANIX 0.21
- PRLD 0.07
- MACD
- ANIX -0.07
- PRLD -0.00
- Stochastic Oscillator
- ANIX 4.95
- PRLD 21.04
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.